New at CADTH — February 2022

News and Events

Discussion Paper and Online Questionnaire for Information Session on a Potential Pan-Canadian Formulary 
On January 18, 2022, Canada's Drug Agency and the pan-Canadian Formulary Advisory Panel hosted an information session on the panel’s work to date. A discussion paper summarizing the panel’s interim recommendations is available as is an online questionnaire to provide your feedback on specific aspects of the panel’s work. The deadline to submit feedback is February 25, 2022.

Information Session on CADTH’s New Post-Market Drug Evaluation Program 
Canada's Drug Agency is expanding its expertise in the management of drugs in Canada with the creation of a new Post-Marketing Drug Evaluation (PMDE) Program. Visit the program’s webpage, read our program overview, and register to join our information session on February 8 that will provide details and guide potential applicants, including researchers and methodologists, on how to respond to our Request for Proposals for grant funding. 

Canada's Drug Agency Lecture — COVID-19 and Its Impact on Cancer Patients, Survivors, and Health Systems: Evidence, Economics, and Ethics 
This lecture will look at global modelling efforts to understand the impact of COVID-19 on cancer screening and treatment, early data on patient-reported experiences and outcomes, and the urgent need for more robust economic and ethics frameworks for allocating scarce resources during pandemics. Registration is required.

Self-Sampling Devices for HPV Testing: A Tool to Improve Cervical Cancer Screening 
CADTH, in collaboration with the Canadian Partnership Against Cancer (CPAC), examined the available evidence on the use of self-sampling devices for HPV testing.

Canada's Drug Agency Reimbursement Reviews

We recently issued the following Reimbursement Recommendations:

• osimertinib (Tagrisso) for non–small cell lung cancer
• enfortumab vedotin (Padcev) for locally advanced or metastatic urothelial carcinoma
• macitentan and tadalafil (Opsynvi) for pulmonary arterial hypertension
• galcanezumab (Emgality) for prevention of migraine.

Canada's Drug Agency Horizon Scanning

We have published the following Horizon Scans:

• Renal Denervation for People With Hypertension ― Health Technology Update

Canada's Drug Agency Health Technology Reviews

We have published the following Health Technology Reviews:

• Orthopedic Footwear for People With Lower-Limb Conditions ― Rapid Review
• Adalimumab for the Treatment of Adults With Non-Infectious Uveitis — Rapid Review
• Floatation Therapy for Physical Conditions — Rapid Review
• Pharmacogenomic Testing in Depression: A 2021 Update — Rapid Review
• Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma — Rapid Review
• Evaluations of Virtual Care — Environmental Scan
• The Small House Model for Long-Term Care — Environmental Scan
• Nirmatrelvir and Ritonavir (Paxlovid) for Mild to Moderate COVID-19 — Technology Review
• Portable MRI for Use at the Bedside — CMII Report
• The Implementation Considerations of PET-CT — CMII Report
• The Role of PET-CT in Drugs Targeting Amyloid-Beta in Alzheimer Disease: Part 2 — CMII Report
• Impacts of COVID-19 on First Nations, Inuit, and Métis Populations in Canada – Quick Start
• Impact of the COVID-19 Pandemic on the Physical and Mental Well-Being of Health Care Workers – Quick Start

Canada's Drug Agency Reference Lists

We have published the following Reference Lists:

• Intraoperative Navigation Tools for Total Hip Arthroplasty
• Axicabtagene Ciloleucel and Tisagenlecleucel for Diffuse Large B-cell Lymphoma
• Screening for Cognitive Impairment in Asymptomatic Community-Dwelling Older Adults: A 2022 Update
• Contact Precautions for Patients Previously Positive for Antibiotic Resistant Organisms: Guidelines

OTHER Canada's Drug Agency Tools

Hospital News articles:

• “Dementia Care In Canada: Implementation Considerations And The Lived Experience Perspective”
• “Remote Monitoring Programs For Chronic Heart Conditions: Implementation Considerations”

Summary Tools:

• Considerations for the Implementation of Remote Monitoring Programs in Canada

In Brief:

• Clinical Effectiveness of Opioid Substitution Treatment
• Cost-Effectiveness and Guidelines for Opioid Substitution Treatment
• Remote Monitoring for Cardiac Conditions: A Review

Tell Us What You Think

We love hearing how our products and services are influencing health care policies, clinical practices, and patient outcomes. If you have a success story to share, please get in touch with your Canada's Drug Agency Liaison Officer.

Canada's Drug Agency E-Alerts: Subscribe to receive the latest Canada's Drug Agency news, reports, feedback opportunities, and events.